Acquisitions, Assets and Liabilities Held for Sale, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment - Bamboo Therapeutics (Details) - USD ($) $ in Millions			3 Months Ended	9 Months Ended
		Aug. 01, 2016	Apr. 03, 2016	Oct. 02, 2016	Sep. 27, 2015	Dec. 31, 2015
Business Acquisition [Line Items]
Cash payments for acquisition, net of cash acquired	[1]			$ 17,679	$ 16,322
Goodwill	[2]			$ 56,281		$ 48,242
Bamboo Therapeutics [Member]
Business Acquisition [Line Items]
Payment to acquire the remaining equity		$ 150
Maximum amount of potential milestone payments		495
Total fair value of consideration transferred		331
Payments for acquisitions, cash portion		130	$ 43
Cash payments for acquisition, net of cash acquired		101
Contingent consideration incurred		157
Fair value of previously held equity interest		44
Goodwill		130
Deferred tax liabilities		94
Other Income (Expense) [Member] | Bamboo Therapeutics [Member]
Business Acquisition [Line Items]
Gain recognized upon acquisition of remaining interest in acquiree		1
In Process Research and Development [Member] | Bamboo Therapeutics [Member]
Business Acquisition [Line Items]
IPR&D		$ 325

[1] Amounts may not add due to rounding.

[2] Amounts may not add due to rounding.